Quizartinib with decitabine and venetoclax (triplet) is highly active in patients with FLT3-ITD mutated acute myeloid leukemia (AML).

Musa Yilmaz,Hagop M. Kantarjian,Muharrem Muftuoglu,Tapan M. Kadia,Marina Konopleva,Gautam Borthakur,Courtney D. DiNardo,Naveen Pemmaraju,Nicholas J. Short,Yesid Alvarado,Guillermo Montalban Bravo,Carissa Jurisprudenica,Allison Pike,Maro Ohanian,Elias Jabbour,Guillermo Garcia-Manero,Vivian Ruvolo,Farhad Ravandi,Michael Andreeff,Naval Daver

Quizartinib with decitabine and venetoclax (triplet) is highly active in patients with FLT3-ITD mutated acute myeloid leukemia (AML).

2021

e19019Background: The outcomes in patients (pts) with newly diagnosed FLT3 mutated AML who are ineligible for intensive induction chemotherapy are poor. Added to a low intensity chemotherapy backbo...

Keywords:

in patient
flt3 itd
Medicine
Chemotherapy
Quizartinib
Oncology
Internal medicine
Decitabine
Myeloid leukemia
Induction chemotherapy
Venetoclax

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations